23-03-2022
Latest In Brief
- InBriefBRIEF—Sun Pharma settles antitrust claims against Ranbaxy for $485 million
24-03-2022
- InBriefBRIEF—Sobi to cease ReFacto manufacturing for Pfizer
23-03-2022
- InBriefBRIEF—Voyager Therapeutics names Alfred Sandrock as CEO
22-03-2022
- InBriefBRIEF—Ipsen appoints Guy Oliver as general manager, UK & Ireland
21-03-2022
Latest Pharmaceutical News
FDA green light for Novartis’ Pluvicto
24-03-2022
Swiss pharma giant Novartis edged up 1% today after it announced that the US Food and Drug Administration…
- ArticleEtrasimod UC trial hints at early vindication of Pfizer’s Arena buy
24-03-2022
- ArticlePortable Blender, Personal Size Blender for Smoothies, Juice and
24-03-2022
- ArticlePharma reaction to UK Spring Statement 2022
24-03-2022
- ArticleMerck announces replacement for retiring Roy Baynes as GCD
23-03-2022
Latest Biotechnology News
Mini-Vci - Automotive Diagnostic Cables USB Connector Automotive
24-03-2022
Germany’s MorphoSys shares were up 7.5% at 25..69 euros, after along with partner USA-based Incyte,…
- ArticleChanging of the guard at Sosei Heptares
24-03-2022
- ArticlePhase III cervical cancer miss for AstraZeneca’s Imfinzi
24-03-2022
- ArticleLilly's checkpoint blocker rejected for lung cancer indication in USA
24-03-2022
- ArticleLigand spin-out spies share of growing antibody discovery market
24-03-2022
Latest Generics News
STADA Arzneimittel’s 2021 above-market development
22-03-2022
Germany’s STADA Arzneimittel outperformed the market again in 2021, overcoming challenging trading…
- ArticleIndian companies to share in cancer drug's $12 billion pie
21-03-2022
- ArticleCompany billed as Europe’s API giant set for Euronext listing
18-03-2022
- Article35-company generics deal for Pfizer’s Paxlovid prompts MSF backlash
17-03-2022
- ArticleCivica Rx will provide strong competition to lower the cost of insulins
17-03-2022
Latest Biosimilars News
Henlius gears up for PD1 commercialization, biosimilar global supply
22-03-2022
China’s Fosun Pharma’s biotech arm Henlius is preparing to get its PD1 antibody serplulimab into…
- ArticleWHO proposed exemption from biosimilar trials set to trigger biosimilar boom in India
14-03-2022
- ArticleHealth Canada approves first Lucentis biosimilar
10-03-2022
- ArticleAlvotech and AbbVie settle Humira biosimilar patent dispute
09-03-2022
- ArticleFDA announces funding opportunity for the BsUFA III regulatory science program
08-03-2022